LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells

키워드

참고문헌 (48)

1. Westphal M, "The neurobiology of gliomas: from cell biology to the development of therapeutic approaches", Nat Rev Neurosci, 12, pp.495~508 (2011)
2. Bello L, "Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo", Cancer Res, 61, pp.7501~7506 (2001)
3. Hösli P, "Malignant glioma: should chemotherapy be overthrown by experimental treatments?", nn Oncol, 9, pp.589~600 (1998)
4. Athanassiou H, "Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme", J Clin Oncol, 23, pp.2372~2377 (2005)
5. Higgins CF, "Multiple molecular mechanisms for multidrug resistance transporters", Nature, 446, pp.749~757 (2007)
6. Calatozzolo C, "Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma", J Neurooncol, 74, pp.113~121 (2005)
7. Stupp R, "Chemoradiotherapy in malignant glioma: standard of care and future directions", J Clin Oncol, 25, pp.4127~4163 (2007)
8. Jennings MT, "The molecular genetics of therapeutic resistance in malignant astrocytomas", Am J Pharmacogenomics, 1, pp.93~99 (2001)
9. Tentori L, "Recent approaches to improve the antitumor efficacy of temozolomide", Curr Med Chem, 16, pp.245~257 (2009)
10. Suzuki Y, "cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains", J Biol Chem, 271, pp.22522~22527 (1996)
11. Nilsson J, "Cloning, characterization, and expression of human LIG1", Biochem Biophys Res Commun, 284, pp.1155~1161 (2001)
12. Nilsson J, "LRIG1 protein in human cells and tissues", Cell Tissue Res, 312, pp.65~71 (2003)
13. Thomasson M, "LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis", Br J Cancer, 89, pp.1285~1289 (2003)
14. Ye F, "Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4", Ai Zheng, 23, pp.1149~1154 (2004)
15. Miller JK, "Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer", Cancer Res, 68, pp.8286~8294 (2008)
16. Thomasson M, "LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer", Int J Cancer, 128, pp.2843~2852 (2011)
17. Lu L, "LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development", J Pathol, 229, pp.608~620 (2013)
18. Shattuck DL, "Carraway KL 3rd, et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy", Mol Cell Biol, 27, pp.1934~1946 (2007)
19. Sheu JJ, "LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling", Oncogene, 33, pp.1375~1384 (2014)
20. Powell AE, "The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor", Cell, 149, pp.146~158 (2012)
21. Yi W, "Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age", Clin Neuropathol, 28, pp.21~27 (2009)
22. Jansen B, "bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice", Nat Med, 4, pp.232~234 (1998)
23. Le Calvé B, "Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression", Neoplasia, 12, pp.727~739 (2010)
24. Fedor HL, "Practical methods for tissue microarray construction", Methods Mol Med, 103, pp.89~101 (2005)
25. Fan QW, "EGFR signals to mTOR through PKC and independently of Akt in glioma", Sci Signal, 2, pp.ra4~ (2009)
26. Martens T, "A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo", Clin Cancer Res, 12(20 Pt 1), pp.6144~6152 (2006)
27. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization defines human glioblastoma genes and core pathways", Nature, 455, pp.1061~1068 (2008)
28. Stommel JM, "Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies", Science, 318, pp.287~290 (2007)
29. Hedman H, "LRIG1 a tumour suppressor gene at chromosome 3p14.3?", Acta Oncol, 41, pp.352~354 (2002)
30. Goldoni S, "A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity", Oncogene, 26, pp.368~381 (2007)
31. Hansford LM, "Glial cell line-derived neurotrophic factor (GDNF) family ligands reduce the sensitivity of neuroblastoma cells to pharmacologically induced cell death, growth arrest and differentiation", Neurosci Lett, 389, pp.77~82 (2005)
32. Ledda F, "Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF", J Neurosci, 28, pp.39~49 (2008)
33. Li F, "LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway", Oncol Rep, 25, pp.1629~1637 (2011)
34. Liu B, "Increased leucine-rich repeats and immunoglobulin-like domains 1 expression enhances chemosensitivity in glioma", Neural Regen Res, 32, pp.2516~2520 (2011)
35. Wesarg E, "Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer", Int J Cancer, 121, pp.2387~2394 (2007)
36. He X, "The potential mechanism of chemosensitive difference between 2 types of ovarian cancer", Saudi Med J, 28, pp.1044~1049 (2007)
37. Nordfors K, "Peroxiredoxins and antioxidant enzymes in pilocytic astrocytomas", Clin Neuropathol, 26, pp.210~218 (2007)
38. Sekine I, "A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer", Int J Clin Oncol, 14, pp.112~119 (2009)
39. Wang P, "Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2", Bax, 2010, pp.10, 661~
40. Gur G, "LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation", EMBO J, 23, pp.3270~3281 (2004)
41. Ye F, "Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity", J Neurooncol, 94, pp.183~194 (2009)
42. Khatua S, "Overexpression of the EGFR", FKBP12, Cancer Res, pp.2003, 63[DOI]
43. Lei W, "Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells", Anticancer Res, 19, pp.221~228 (1999)
44. Nogi H, "EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer", Oncol Rep, 21, pp.413~417 (2009)
45. Fornari F, "MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells", Cancer Res, 70, pp.5184~5193 (2010)
46. Li Y, "Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy", Mol Cancer Ther, 8, pp.376~385 (2009)
47. Lin CI, "Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer", Mol Cancer Res, 8, pp.1217~1226 (2010)
48. Zou HY, "An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms", Cancer Res, 67, pp.4408~4417 (2007)

관련 논문AI추천